Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utreglutide for at-risk MASH in adults
ACTRN12625000241437Phase 2Recruiting
- Sponsor
- Sun Pharma
- Start
- May 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Utreglutide with Placebo (2 arms). Primary endpoints: Liver fat content and Liver stiffness. Started May 2025; status: recruiting.
02
Drugs
utreglutide
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on ACTRN12625000241437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000241437.